A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.

Lingvay I, Desouza CV, Lalic KS, Lalic KS, Rose L, Hansen T, Zacho J, Pieber TR

Diabetes care19 Jul 2018Cited by 58 (Europe PMC)

PMID30026333DOI10.2337/dc17-2381PepBankPUB-30026333

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, once-daily semaglutide lowered HbA1c in a dose-dependent way by week 26, from -1.1% at 0.05 mg to -1.9% at 0.3 mg.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered HbA1c more at higher doses over 26 weeks.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change at week 26
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.05, 0.1, 0.2 or 0.3 mg once daily · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.1%
semaglutide 0.05 mg
HbA1c change
−1.9%
semaglutide 0.3 mg
Source sentences
Summary
At week 26, a dose-dependent change in HbA_1c was observed with semaglutide from -1.1% (0.05 mg) to -1.9% (0.3 mg) and with liraglutide from -0.5% (0.3 mg) to -1.3% (1.8 mg) (all P < 0.001 in favor of volume-matched semaglutide dose).
2 context sentences(design, population, supporting numbers)
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633301
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, once-daily liraglutide lowered HbA1c in a dose-dependent way by week 26, from -0.5% at 0.3 mg to -1.3% at 1.8 mg.
In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c more at higher doses over 26 weeks.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at week 26
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.3, 0.6, 1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.5%
liraglutide 0.3 mg
HbA1c change
−1.3%
liraglutide 1.8 mg
Source sentences
Summary
At week 26, a dose-dependent change in HbA_1c was observed with semaglutide from -1.1% (0.05 mg) to -1.9% (0.3 mg) and with liraglutide from -0.5% (0.3 mg) to -1.3% (1.8 mg) (all P < 0.001 in favor of volume-matched semaglutide dose).
2 context sentences(design, population, supporting numbers)
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633302
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide lowered HbA1c more than liraglutide at each volume-matched dose at week 26.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered HbA1c more than liraglutide at matched doses.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus volume-matched liraglutide
Study
n: not reported in source
Comparator
Volume-matched liraglutide dose
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.05, 0.1, 0.2 or 0.3 mg once daily · 26 weeksAs given in this study (human).
Source sentences
Summary
At week 26, a dose-dependent change in HbA_1c was observed with semaglutide from -1.1% (0.05 mg) to -1.9% (0.3 mg) and with liraglutide from -0.5% (0.3 mg) to -1.3% (1.8 mg) (all P < 0.001 in favor of volume-matched semaglutide dose).
2 context sentences(design, population, supporting numbers)
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633303
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, semaglutide lowered HbA1c more than pooled placebo, which changed by -0.02%.
In plain wordsIn adults with type 2 diabetes, semaglutide lowered HbA1c more than placebo.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change versus placebo
Study
n: not reported in source
Comparator
Placebo (pooled)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.05, 0.1, 0.2 or 0.3 mg once daily · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.02%
pooled placebo
Source sentences
Summary
Change with pooled placebo was -0.02% (P < 0.0001 vs. semaglutide).
2 context sentences(design, population, supporting numbers)
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633304
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, gastrointestinal disorders were the most common adverse events with semaglutide, in 32.8-54.0% of patients.
In plain wordsIn adults with type 2 diabetes, stomach and gut side effects were the most common problems with semaglutide.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.05, 0.1, 0.2 or 0.3 mg once daily · 26 weeksAs given in this study (human).
Measurements
GI adverse events
32.8 to 54%
semaglutide
Source sentences
Summary
Gastrointestinal (GI) disorders were the most common adverse events (AEs) with semaglutide and liraglutide, occurring in 32.8-54.0% and 21.9-41.5% of patients, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633305
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, gastrointestinal disorders were the most common adverse events with liraglutide, in 21.9-41.5% of patients.
In plain wordsIn adults with type 2 diabetes, stomach and gut side effects were the most common problems with liraglutide.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.3, 0.6, 1.2 or 1.8 mg once daily · 26 weeksAs given in this study (human).
Measurements
GI adverse events
21.9 to 41.5%
liraglutide
Source sentences
Summary
Gastrointestinal (GI) disorders were the most common adverse events (AEs) with semaglutide and liraglutide, occurring in 32.8-54.0% and 21.9-41.5% of patients, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633306
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, semaglutide caused gastrointestinal adverse events more often than liraglutide (32.8-54.0% versus 21.9-41.5%).
In plain wordsIn adults with type 2 diabetes, semaglutide caused more stomach and gut side effects than liraglutide.
Peptide
Semaglutide
Outcome
IncreaseGastrointestinal adverse events versus liraglutide
Study
n: not reported in source
Comparator
Liraglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.05, 0.1, 0.2 or 0.3 mg once daily · 26 weeksAs given in this study (human).
Measurements
GI adverse events
32.8 to 54%
semaglutide
GI adverse events
21.9 to 41.5%
liraglutide
Source sentences
Summary
Gastrointestinal (GI) disorders were the most common adverse events (AEs) with semaglutide and liraglutide, occurring in 32.8-54.0% and 21.9-41.5% of patients, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA_1c compared with liraglutide or placebo but with a higher frequency of GI AEs.
Summary · context
This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA_1c 7.0-10.0% (53-86 mmol/mol) and treated with diet and exercise with or without metformin.
Summary · context
Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group).
Report a problemFND-3002633307

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02461589

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 70621 Sept 2015 to 13 Oct 2016

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 31 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.